Kyntra Bio (MEX:KYNB) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KYNB Kyntra Bio Inc MEX:KYNB
48 GF Score
Price MXN119.00
GF Value MXN72.51
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Short-term investments?

Short-term investments only applies to insurance companies.

MEX:KYNB
48GF Score
Kyntra Bio Inc MEX:KYNB
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN119.00 is trading 64.1% above its estimated GF Value™ of MXN72.51. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for MEX:KYNB:

  • Short-term investments:
  • GF Value™: MXN72.51 vs. price of MXN119.00 (64.1% above fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
48GF Score

Get the complete analysis for MEX:KYNB

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN119.00
Price
MXN72.51
GF Value